News

2021 Highlighted News!

  • Brandon Dale, Drs. Kwang-Su Park, H. Ümit Kaniskan and Jian Jin and Their Collaborators Published in Nature Reviews Cancer

The research team led by Dr. Jian Jin, the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery, and Dr. Yue Xiong, William R. Kenan Jr. Distinguished Professor at University of North Carolina at Chapel Hill, has published a review article entitled “Advancing Targeted Protein Degradation for Cancer Therapy” in Nature Reviews Cancer (https://www.nature.com/articles/s41568-021-00365-x). Dr. Jin’s lab is a pioneer and leader in discovering and characterizing first-in-class small-molecule degraders (also known as proteolysis targeting chimeras (PROTACs)) that target oncogenic proteins and developing novel technologies for advancing the targeted protein degradation field. The Jin lab’s work in this area has been published in high impact journals such as Nature Chemical Biology, Science Advances, Nature Cancer, and Journal of The American Chemical Society.

 

  • Drs. He Chen, H. Ümit Kaniskan and Jian Jin and Their Collaborators Published a Research Article Entitled “TF-PROTACs Enable Targeted Degradation of Transcription Factors” in Journal of American Chemical Society

The research team led by Dr. Jian Jin, the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery, and Dr. Wenyi Wei, a Professor at Harvard Medical School, developed a novel technology, termed as TF-PROTACs, for degrading transcription factors (TFs) by hijacking the cellular ubiquitin-proteasome system (https://pubs.acs.org/doi/10.1021/jacs.1c03852). This technology provides a generalizable platform to achieve selective degradation of TFs, many of which are oncogenic proteins, and a universal strategy for targeting most “undruggable” TFs.

 

  • Drs. He Chen, H. Ümit Kaniskan and Jian Jin and Their Collaborators Published a Research Article Entitled “Cancer Selective Target Degradation by Folate-Caged PROTACs” in Journal of American Chemical Society

The research team led by Dr. Jian Jin, the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery, and Dr. Wenyi Wei, a Professor at Harvard Medical School, developed a novel folate-caging technology as a generalizable platform for selective targeting cancer cells over normal cells by proteolysis targeting chimeras (PROTACs), a new class of promising therapeutic modalities (https://pubs.acs.org/doi/10.1021/jacs.1c00451). Prior to this discovery, the same research team developed a novel caging strategy, termed as “opto-PROTACs”, that enables the degradation of protein targets in a spatiotemporal manner by photo uncaging. The work was published in Science Advances in 2020 (https://advances.sciencemag.org/content/6/8/eaay5154). These novel technologies provide generalizable platforms for enabling PROTACs to be precision medicines.

 

  • Dr. Jian Jin Has Received a New Multiple-PI R01 Grant from NCI to Develop Novel Therapeutics for Treating MLL-rearranged Leukemias

Dr. Jian Jin (the contact PI), the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery, and Dr. Hong Wen (the MPI), an Associate Professor at Van Andel Research Institute, have received a new five-year multiple-PI R01 grant from the National Cancer Institute of the National Institutes of Health. The mixed-lineage leukemia (MLL) gene rearrangements account for approximately 80% of infant acute lymphoblastic leukemia and 35-50% of infant acute myeloid leukemia. Patients bearing rearrangements of the MLL gene are associated with dismal prognosis. The research team led by Drs. Jin and Wen will target ENL, an MLL fusion partner, which functions as a reader of histone acetylation and is essential for growth and survival of the MLL-rearranged leukemic cells. Dr. Jin’s laboratory is a pioneer and leader in discovering novel heterobifunctional small-molecule degraders (also known as proteolysis targeting chimeras (PROTACs)) targeting oncogenic proteins. Using the PROTAC technology, the research team will develop first-in-class PROTAC degraders of ENL as a novel therapeutic strategy for treating MLL-rearranged leukemias.

 

  • Dr. Jian Jin’s Laboratory Received a Major Grant from DARPA to Create Novel and Safe Psychiatric Medications

Dr. Jian Jin, the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery, is part of a team of internationally acclaimed scientists who has received a four-year, $26,975,142 cooperative agreement from the U.S. Defense Advanced Research Project Agency (DARPA) to generate novel and safe medications for rapidly and effectively treating psychiatric disorders such as depression, anxiety and substance abuse. The research team led by Dr. Bryan Roth at University of North Carolina at Chapel Hillalso includes Drs. Brian Shoichet and Nevan Kroganat University of California at San Francisco, Drs. Georgios Skiniotis and Ron Dror at Stanford University, and Dr. William Wetsel at Duke University. The team has developed innovative methods and technologies and will utilize them to create and advance novel biased agonists of G protein-coupled receptors as drug candidates.

 

  • Drs. Jian Jin and H. Ümit Kaniskan Published in Nature Reviews Drug Discovery

Dr. Jian Jin, the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery, and Dr. H. Ümit Kaniskan, Associate Professor of Pharmacological Sciences and Associate Director of the Mount Sinai Center for Therapeutics Discovery, along with their collaborators Drs. Or Gozani and Kamakoti P. Bhat at Stanford University have published a review article entitled “Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease” in Nature Reviews Drug Discovery (https://www.nature.com/articles/s41573-020-00108-x). Dr. Jin’s lab is a pioneer and leader in discovering selective small-molecule inhibitors of protein lysine methyltransferases (KMTs, also known as histone lysine methyltransferases), an important class of epigenetic enzymes that play critical roles in human diseases including cancer. The Jin lab has discovered numerous novel, potent and selective small-molecule inhibitors of KMTs including EZH2, G9a/GLP and SETD8 since 2008.

 

  • Kwang-Su Park, Ph.D. received 2019-2020 Postdoctoral Award for Excellence in Mentoring

The Office of Postdoctoral Affairs and the Postdoc Executive Committee at the Icahn School of Medicine at Mount Sinai (ISMMS) announced award winner for “The Excellence in Mentoring Award” as Kwang-Su Park, Ph.D., Postdoctoral fellow in Dr. Jian Jin Lab.